Hongjun Jin1, Xiang Zhang1, Xuyi Yue1, Hui Liu1, Junfeng Li1, Hao Yang1, Hubert Flores2, Yi Su2, Stanley M Parsons3, Joel S Perlmutter4, Zhude Tu5. 1. Department of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA. 2. Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA. 3. Department of Chemistry and Biochemistry, University of California, Santa Barbara, CA 93106, USA. 4. Department of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA; Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA. 5. Department of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA. Electronic address: tuz@mir.wustl.edu.
Abstract
INTRODUCTION: Deficits in cholinergic function have been found in the aged brain and in neurodegenerative diseases including Alzheimer's disease (AD) and Parkinson's disease (PD). The vesicular acetylcholine transporter (VAChT) is a reliable biomarker for the cholinergic system. We previously reported the initial in vitro and ex vivo characterization of (-)-[(11)C]TZ659 as a VAChT specific ligand. Here, we report the in vivo specificity, tracer kinetics, and dose-occupancy studies in the nonhuman primate brain. METHODS: MicroPET brain imaging of (-)-[(11)C]TZ659 was performed under baseline conditions in two male macaques. Tracer kinetic modeling was carried out using a two-tissue compartment model (2TCM) and Logan plot with arterial blood input function and using a simplified reference tissue model (SRTM) and Logan plot (LoganREF) without blood input. Specificity for VAChT was demonstrated by pretreatment with (+)-pentazocine, (-)-vesamicol, or S-(-)-eticlopride. Target occupancy (Occ) was calculated following pretreatment with escalating doses of (-)-vesamicol. RESULTS: Baseline PET imaging revealed selective retention in the striatum with rapid clearance from the cerebellar hemispheres as a reference region. Total volume of distribution (VT) values derived from both 2TCM and Logan analysis with blood input revealed ~3-fold higher levels of (-)-[(11)C]TZ659 in the striatum than the cerebellar hemispheres. Injection of (-)-vesamicol either as a blocking or displacing agent significantly reduced striatal uptake of (-)-[(11)C]TZ659. In contrast, pretreatment with the sigma-1 ligand (+)-pentazocine had no impact. Pretreatment with the S-(-)-eticlopride, a dopamine D2-like receptor antagonist, increased striatal uptake of (-)-[(11)C]TZ659. Striatal binding potential (BPND, range of 0.33-1.6 with cerebellar hemispheres as the reference region) showed good correlation (r(2)=0.97) between SRTM and LoganREF. Occupancy studies found that ~0.0057 mg/kg of (-)-vesamicol produced 50% VAChT occupancy in the striatum. CONCLUSION: (-)-[(11)C]TZ659 demonstrated specific and reversible VAChT binding and favorable pharmacokinetic properties for assessing the density of VAChT in the living brain.
INTRODUCTION: Deficits in cholinergic function have been found in the aged brain and in neurodegenerative diseases including Alzheimer's disease (AD) and Parkinson's disease (PD). The vesicular acetylcholine transporter (VAChT) is a reliable biomarker for the cholinergic system. We previously reported the initial in vitro and ex vivo characterization of (-)-[(11)C]TZ659 as a VAChT specific ligand. Here, we report the in vivo specificity, tracer kinetics, and dose-occupancy studies in the nonhuman primate brain. METHODS: MicroPET brain imaging of (-)-[(11)C]TZ659 was performed under baseline conditions in two male macaques. Tracer kinetic modeling was carried out using a two-tissue compartment model (2TCM) and Logan plot with arterial blood input function and using a simplified reference tissue model (SRTM) and Logan plot (LoganREF) without blood input. Specificity for VAChT was demonstrated by pretreatment with (+)-pentazocine, (-)-vesamicol, or S-(-)-eticlopride. Target occupancy (Occ) was calculated following pretreatment with escalating doses of (-)-vesamicol. RESULTS: Baseline PET imaging revealed selective retention in the striatum with rapid clearance from the cerebellar hemispheres as a reference region. Total volume of distribution (VT) values derived from both 2TCM and Logan analysis with blood input revealed ~3-fold higher levels of (-)-[(11)C]TZ659 in the striatum than the cerebellar hemispheres. Injection of (-)-vesamicol either as a blocking or displacing agent significantly reduced striatal uptake of (-)-[(11)C]TZ659. In contrast, pretreatment with the sigma-1 ligand (+)-pentazocine had no impact. Pretreatment with the S-(-)-eticlopride, a dopamine D2-like receptor antagonist, increased striatal uptake of (-)-[(11)C]TZ659. Striatal binding potential (BPND, range of 0.33-1.6 with cerebellar hemispheres as the reference region) showed good correlation (r(2)=0.97) between SRTM and LoganREF. Occupancy studies found that ~0.0057 mg/kg of (-)-vesamicol produced 50% VAChT occupancy in the striatum. CONCLUSION:(-)-[(11)C]TZ659 demonstrated specific and reversible VAChT binding and favorable pharmacokinetic properties for assessing the density of VAChT in the living brain.
Authors: Myria Petrou; Kirk A Frey; Michael R Kilbourn; Peter J H Scott; David M Raffel; Nicolaas I Bohnen; Martijn L T M Müller; Roger L Albin; Robert A Koeppe Journal: J Nucl Med Date: 2014-01-30 Impact factor: 10.057
Authors: Steven T DeKosky; Milos D Ikonomovic; Scot D Styren; Laurel Beckett; Stephen Wisniewski; David A Bennett; Elizabeth J Cochran; Jeffrey H Kordower; Elliott J Mufson Journal: Ann Neurol Date: 2002-02 Impact factor: 10.422
Authors: Zhude Tu; Simon M N Efange; Jinbin Xu; Shihong Li; Lynne A Jones; Stanley M Parsons; Robert H Mach Journal: J Med Chem Date: 2009-03-12 Impact factor: 7.446
Authors: Hongjun Jin; Xuyi Yue; Hui Liu; Junbin Han; Hubert Flores; Yi Su; Stanley M Parsons; Joel S Perlmutter; Zhude Tu Journal: J Neurochem Date: 2018-03-25 Impact factor: 5.372
Authors: Xuyi Yue; Hongjun Jin; Hui Liu; Zonghua Luo; Xiang Zhang; Kota Kaneshige; Hubert P Flores; Joel S Perlmutter; Stanley M Parsons; Zhude Tu Journal: Org Biomol Chem Date: 2017-06-21 Impact factor: 3.876
Authors: Xuyi Yue; Zonghua Luo; Hui Liu; Kota Kaneshige; Stanley M Parsons; Joel S Perlmutter; Zhude Tu Journal: Bioorg Med Chem Lett Date: 2018-09-24 Impact factor: 2.823
Authors: Anna Schildt; Erik F J de Vries; Antoon T M Willemsen; Bruno Lima Giacobbo; Rodrigo Moraga-Amaro; Jürgen W A Sijbesma; Aren van Waarde; Vesna Sossi; Rudi A J O Dierckx; Janine Doorduin Journal: Mol Pharm Date: 2020-02-17 Impact factor: 4.939